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Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), has been a 
component of first line antiretroviral treatment in the South African HIV/AIDS 
programme since 2004.  Similarly, it is extensively used in ART programmes in other 
low and middle incomes countries.  The natural history of the previously reported EFV 
drug induced liver injury (DILI), is unknown.   
 
Objectives 
To establish causality assessment for the drug-induced liver injury and elucidate the 
natural history of EFV DILI by observing a cohort of patients through documenting all 
the factors influencing the patterns of clinical and histological injury, the time to clinical 
and biochemical recovery, the associated mortality rate and to establish if any 
demographic or clinical factors predict poor outcomes.  
 
Methods 
Patients were prospectively included after establishing causality criteria for EFV DILI. 
Clinical, demographic and histological features were carefully documented from the 
time of presentation and through follow up.  Prednisone at 0.25-0.5mg/kg was initiated 
at the discretion of the treating hepatologist. Risk factors for severe injury or death and 
time to event (full clinical recovery and full biochemical recovery) were analyzed. 
 
Results 
50 patients were included in the analysis, median age 34 (IQR 29-39) years, men 
significantly older than women, p=0.014.  Most (92%) were female gender, and of 
black African ethnicity (86%). The median duration on ART at time of presentation 
was 6.5 months with half of the women initiating ART during pregnancy at a median 
gestation of 24 weeks (IQR 11 – 36).  Median CD4 nadir at ART treatment initiation 
was 517 cells/mm3, with no significant difference (p=NS) in CD4 nadir in those 
pregnant or not.  Median RUCAM score was 7 and of the 66% of patients who had liver 
biopsies, 3 histological patterns were identified: submassive necrosis (57,5%), non-
specific hepatitis (36%) and mixed cholestatic hepatitis (6%).  Multivariate analysis 
suggested predictors for the development of submassive necrosis included age >30 
years [OR 0.86 (0.15-0.97), p=0.02], pregnancy [OR 6.9 (1.34 – 35.6), p=0.02];         
CD4 >350 [OR, 7.1 (1.5-31.9), p=0.02] but not alcohol use [OR 1.17 (0.72-1.18); 
p=0.07]. For the non-specific hepatitis group, only pregnancy predicted [OR 8.7 (1.3-
58.2), p=0.03].  The mortality rate was 14%, median time from admission to death was 
15 days with the median duration to initial hospital discharge 33 (IQR 24 -52) days. 
Biochemical recovery was prolonged necessitating a follow up period of more than a 





EFV DILI is a severe injury with significant inpatient mortality and morbidity requiring 





Literature Review: Efavirenz Drug Induced Liver Injury 
 
Introduction 
Drug induced liver injury (DILI) is an important cause of acute, acute-on-chronic and, 
less commonly, chronic liver disease. It has an estimated incidence of 14 to 19 cases 
per 100,000 persons with  jaundice occurring in 30% of cases.1,2 The diagnosis of  DILI 
is dependent on establishing causality and excluding other causes of liver injury. There 
are three phenotypes of DILI which have distinct clinical profiles: direct (intrinsic), 
indirect and idiosyncratic hepatotoxicity.3  
 
Direct DILI is typically dose-related, predictable, reproducible in animal models and 
has a short latency period (hours to days) e.g paracetamol induced liver injury. Indirect 
DILI is caused by the action of the drug i.e induction of a new liver condition or an 
exacerbation of a preexisting condition, e.g. induction of immune-mediated hepatitis or 
worsening of hepatitis B (HBV) or C (HCV). 3 
 
Idiosyncratic hepatotoxicity is caused by agents that have little or no intrinsic 
toxicity, is not dose related, is unpredictable and not reproducible in animal models 
with a variable latency period of days to weeks. It is rare, typically occurring after 1 in 
2000 to 1 in 100,000 patient-exposures.3 Acute hepatocellular hepatitis is the most 
common manifestation of idiosyncratic drug induced liver injury and is marked by a 
latency period, which generally ranges from 5 to 90 days.3 These cases tend to be more 
severe and can be associated with a high mortality rate, in keeping with “Hy’s Law”, 
which states that jaundice and a hepatocellular injury from a drug carries a 10% 
mortality rate.4 
 
Liver disease in the context of  human immunodeficiency virus (HIV) can result from 
a variety of aetiological factors. These include direct and indirect effects of the virus 
itself, opportunistic infections due to immunosuppression, immune reconstitution 
inflammatory  syndrome (IRIS) as well medication used in the management of the 
disease and its complications. This results in varied biochemical and clinical 
presentations depending on the underlying causative pathophysiological mechanisms 
and patient comorbidities.5 
 
Non specific elevation of liver enzymes is a common complication of HIV treatment. 
6,7 DILI is a common cause of liver injury in HIV with frequent causative drugs 
including antiretrovirals (ARVs), anti-tuberculosis (TB) drugs as well as antimicrobials 
used in the treatment of, or prophylaxis against, various opportunistic infections. These 
include, amongst others, cotrimoxazole and fluconazole. DILI due to antiretroviral 
therapy (ART) ranges from asymptomatic elevation of liver enzymes to fulminant liver 
failure and death.8  
 
ART- induced liver failure was seen in approximately 10% of HIV patients, with life-
threatening events appearing at a rate of 2.6 per 100 person years in retrospective 
analysis.5,9 Grade 3 and grade 4 elevations of liver enzymes occurred in between 1% 
and 14% of patients using combination ART. 5,10 There are four major pathways of 
ART-associated hepatoxicity. These include mitochondrial toxicity, hypersensitivity 





Efavirenz (EFV) is an antiretroviral (ARV) drug that acts by noncompetitive binding 
to and inhibition of the HIV reverse transcriptase (RT), thereby inhibiting HIV viral 
replication. EFV belongs to the nonnucleoside reverse transcriptase inhibitor (NNRTI) 
class of ARVs together with nevirapine (NVP) which has a similar mechanism of 
action, but little to no structural similarity. EFV was first approved for use by the Food 
and Drug Administration (FDA) in the United States in 1998 and is currently used in 
combination with other antiretroviral agents in many first line ARV regimens, 
particularly in middle to low income countries, including South Africa.  EFV is 
available generically in fixed dose combination (FDC) with emtricitabine (200 mg) and 
tenofovir (300 mg) under the brand names Atripla, Odimmune and Atroiza. The 
recommended dose of efavirenz in adults is 600 mg orally once daily. 
 
The aim of this literature review was to explore the international and local data relating 
to EFV DILI. The focus was to extract data relating to clinical characteristics of the 
injury, associated morbidity and mortality, risk factors associated with the injury, 
predictors for poor outcomes, associated complications and possible molecular 
mechanisms involved. International trends and data were compared to limited local data 
available in sub-Saharan Africa. Relevant literature regarding the pharmacodynamics 





A literature search was performed using PubMed, Google Scholar and Medline 
databases using online resources provided by the University of Cape Town.  Full-text 
articles were identified from 2002 to 2019. The terms used for the search included 
“efavirenz drug induced liver injury”, “efavirenz hepatotoxicity”, “non-nucleoside 
reverse transcriptase (NNRTI) hepatotoxicity”, “non-nucleoside reverse transcriptase 
(NNRTI) drug induced liver injury”, “antiretroviral (ARV) drug induced liver injury”, 
“antiretroviral therapy (ART) drug induced liver injury”, “antiretroviral (ARV) 
hepatotoxicity”, “antiretroviral therapy (ART) hepatotoxicity”,    “efavirenz 
pharmacogenetics”, “efavirenz pharmacokinetics”, “safety and tolerability of 
efavirenz” and “efavirenz safety in pregnancy”. The articles were restricted to those 
written in English. 
 
Articles were imported into EndNote Desktop version X9 and categorized. Citations 
and referencing to articles used in the literature review were inserted using the EndNote 
citation plugin in Microsoft Word for Mac 2018 version 16.19. A total of 82 articles 













Efavirenz Drug Induced Liver Injury 
 
Incidence 
DILI is a well-recognized complication of ART.11 It is a complex clinical problem 
which often results in hospitalization and adverse patient outcomes.12 Various patterns 
of liver injury are associated with different classes of ART depending on several factors 
including the pathway of metabolism. DILI was found to be the most common finding 
on liver biopsy in a cohort of 301 HIV positive patients at a tertiary hospital in Cape 
Town. This was attributed to various classes of ART, Cotrimoxazole and anti-
tuberculosis (TB) therapy.13  
 
Even though hepatotoxicity is well described within the NNRTIs class of ARVS, it is 
NVP as opposed to EFV that has the higher reported incidence of DILI. In a recent 
meta-analysis comparing EFV to NVP, patients receiving NVP were more likely to 
experience any grade of hepatotoxicity (OR 1.5, 95% CI 1.3 – 1.8) or severe 
hepatotoxicity (OR 3.3, 95% CI 2.5 – 4.2) compared to patients on EFV. This 
hypersensitivity reaction is marked by rash, eosinophilia and hepatitis; and typically 
occurs early within the first three months of taking NVP.14  
 
A South African study where first line ART included EFV found an overall rate of 7.7 
episodes of severe hepatotoxicity per 100 person-years.15 Therefore, although drug 
hepatotoxicity with EFV is well recognized, it is thought to occur at a frequency far 
less than NVP.  
 
Clinical features 
While derangement of serum aminotransferases (above five time the upper limit of 
normal) occurs in 1 – 8% of patients on efavirenz, clinically apparent liver injury from 
EFV is uncommon.16 However, several cases of EFV DILI have been described in the 
literature. 17-26 
 
The mechanism of EFV is postulated to be a hypersensitivity reaction, as the liver injury 
is thought to be immunoallergic in nature. It is described as occurring early in therapy 
(within 1 – 8 weeks) with recovery rapid upon cessation of therapy. Severity ranges 
from mild enzyme elevation to acute hepatocellullar jaundice and fulminant liver 
failure and death.16 
 
Signs of hypersensitivity are less common than with nevirapine hepatotoxicity, but 
symptoms can include rash, fever, and eosinophilia.17,19 The biochemical pattern of 
liver injury is variable, typically cholestatic or mixed, but occasionally hepatocellular. 




In South Africa, however, 3 distinct clinicopathological patterns of Efavirenz-induced 
liver injury were described in 2016 in the largest cohort of patients (81) with EFV 
DILI.27 Histological patterns of EFV DILI are immuno-allergic in nature and in 
standardizing EFV DILI histological patterns of injury reporting, the following 3 
patterns were noted: 
Submassive necrosis (SMN): zonal/panzonal necrosis with inflammatory cell 
infiltrates composed of lymphocytes, plasma cells, and conspicuous eosinophils 
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Nonspecific hepatitis (NSH): portal and/or lobular inflammation particularly in zone 
3 with/without cholate stasis in zone 1, with inflammatory cells including lymphocytes 
and eosinophils. 
Mixed cholestatic hepatitis (MCH): combination of portal tract 
inflammation/interface hepatitis with inflammatory cells, including lymphocytes and 
eosinophils with marked zone 3 bilirubinostasis and a ductular reaction. 
 
One histological pattern, submassive necrosis, was associated with significant 
morbidity and mortality.  The biochemical, clinical and histological features of this 
novel injury indicated that this was a severe injury requiring prolonged hospitalization 
and predictors of risk included female gender, higher CD4 nadir at drug initiation and 
younger age.27  
 
Molecular Mechanisms of EFV DILI 
The molecular mechanism responsible for the development of EFV DILI is largely 
poorly understood. Mitochondrial toxicity is known to be a potential mechanism of 
DILI.28 In the context of ART, this was largely attributed to the nucleoside reverse 
transcriptase inhibitors (NRTIs) on the basis of inhibition of mitochondrial DNA 
polymerase gamma (Pol-γ), the enzyme responsible for mitochondrial DNA (mtDNA) 
replication.29   
 
NNRTIs also cause mitochondrial toxicity by a mechanism independent of 
mitochondrial DNA replication.30 Recent work has provided insight into the possible 
molecular basis for EFV DILI and potential mechanisms of NNRTI mitochondrial 
toxicity, highlighting features of mitochondrial dysfunction in hepatocytes exposed to 
EFV. 
 
In vitro, clinically relevant concentrations of EFV reduce hepatocyte cellular 
proliferation and viability in a concentration dependent manner through an acute 
mitotoxic effect. Mitochondrial function is affected through the induction of oxidative 
stress as well as an increase in mitochondrial mass. Hepatocyte apoptosis is triggered 
by the intrinsic pathway. These effects are partially reversed by antioxidant therapy, 
which is suggestive of a role of reactive oxygen species (ROS) generation.31 
 
Specifically, EFV compromises mitochondrial function by reducing mitochondrial 
respiration through direct inhibition of Complex 1. This leads to a decrease in ATP 
production and mitochondrial membrane potential, and an increase in ROS generation 
together with other metabolic dysfunction including lipid accumulation.32  
 
Furthermore, EFV has a significant effect on the expression of certain stress and 
toxicity genes in human hepatocytes. Up-regulation of Cytochrome P450, family 1, 
subfamily A, polypeptide 1 is indicative of oxidative stress. Increased expression of 
several genes related to oxidative stress and damage, including Methalothionein 2A, 
Heat shock 70 kDA protein 6, Growth differentiation factor 15  and DNA-damage-
inducible transcript 3, also occurs.33  
 
Mitochondrial dysfunction is a major cause of autophagy, which is a mechanism of 
mitochondrial quality control and is generally a cytoprotective response. The process 
of autophagy initially promotes cell survival, however if a threshold is exceeded, 
autophagy overload or stress occurs. Clinically relevant concentrations of EFV induce 
13 
 
autophagy and in particular mitophagy i.e  the degradation of mitochondria by 
autophagy, in human hepatic cells.34 
 
The understanding of the role of autophagy in liver pathophysiology, especially 
regarding DILI, is still limited. However, it is thought that autophagy promotes cell 
survival in response to liver injury including drug toxicity. In the context of EFV DILI, 
autophagy is thought to be a rescue mechanism that promotes hepatocyte survival.35 
 
While moderate levels of EFV activate autophagy, higher concentrations exceed this 
threshold promoting “autophagic stress”. Pharmacological inhibition of autophagy 
worsens the toxic effects of EFV, highlighting the role of autophagy as a rescue 
mechanism enabling cell survival.36 
 
The endoplasmic reticulum (ER) is also vulnerable to the effects of EFV. ER stress 
markers, including C/EBP-homologous protein  and glucose-regulated protein 78  are 
up-regulated in hepatocytes at clinically relevant doses of EFV.  EFV also increases 
cytosolic calcium content and induces morphological changes in the ER indicative of 
ER stress, which results in an “unfolded protein response”. This response is attenuated 
in cells with altered mitochondrial function.37  
 
Hepatocytes that lack functional mitochondria (rho°) are less vulnerable to the effects 
of EFV. EFV-treated rho° cells display less mitochondrial toxicity such as superoxide 
production and altered mitochondrial mass compared to EFV-treated cells with 
functional mitochondria.38  
  
However, the hypothesis that EFV hepatoxicity is related only to mitochondrial toxicity 
does not match the histopathological findings found in these patients. These findings 
include a marked inflammatory cell infiltrate including lymphocytes, plasma cells and 
eosinophils as well as varying degrees of hepatocyte necrosis.27 This is indicative of an 
immunological mechanism as the predominant cause of EFV DILI as opposed to direct 
mitochondrial injury.  
   
Pharmacokinetics of EFV 
EFV is a potent NNRTI that noncompetitively inhibits the HIV-1 RT. It binds directly 
and reversibly to the catalytic site of the RT enzyme and interferes with viral RNA to 
DNA-directed polymerase activities. This renders RT unable to convert viral RNA into 
DNA.39  
 
EFV is well-absorbed after oral administration and attains peak plasma concentrations 
(Cmax) after 3 to 5 hours. EFV has a long serum half-life ranging from 52 to 76 hours 
following single oral doses. Auto-induction results in a half-life of 45 hours following 
long term administration. This allows for once daily administration. Steady-state 
plasma concentrations are achieved between 6 to 10 days.40 Increases in Cmax and area 
under the plasma concentration-time curve (AUC) are dose proportional for 200, 400, 
and 600 mg EFV doses.   
 
EFV is highly bound (>99%) to plasma albumin. It crosses the blood-brain barrier and 
adequate concentrations have been reported in the CSF.41 The pharmacokinetics (PK) 
of EFV has not been studied in renal insufficiency. However, the impact should be 
minimal as less than 1% of a dose is excreted unchanged in the urine. Safety of EFV in 
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patients with significant underlying liver disorders has not been established and caution 
is recommended in patients with mild to moderate liver disease. The use of EFV is 
contraindicated in patients with severe hepatic impairment.40 
 
EFV is metabolised by the cytochrome P450 (CYP)-enzyme system, primarily by the 
CYP3A4 and CYP2B6 isoenzymes to inactive hydroxylated metabolites which are 
subsequently glucuronidated. The oxidative inactive metabolites are excreted into bile 
and urine. In human liver microsomes, EFV undergoes primary oxidative 
hydroxylation to 8-hydroxy EFV (major) and 7-hydroxy EFV (minor) and secondary 
metabolism to 8,14-dihydroxy EFV. The contribution of N-glucuronidation to overall 
clearance of EFV, however, appears minimal. Hence, there are three hydroxylated EFV 
metabolites: 8-hydroxy-EFV, 8,14-dihydroxy-EFV and 7-hydroxy-EFV.42 
 
CYP2B6 is the most important enzyme in the metabolism of EFV to both the 8-hydroxy 
and 7-hydroxy metabolites. Other enzymes that metabolise EFV to a lesser extent are 
CYP3A4, CYP3A5, CYP2A6, CYP2C9 and uridine-glucuronyl-transferases (UGT). 
Metabolites are excreted in the bile and urine with <1% appearing as unchanged drug 
in the urine. CYP2B6 is the principal catalyst of EFV sequential hydroxylation, being 
involved in the formation of the secondary metabolite 8,14-dihydroxy-EFV. 43,44 EFV 
can also be hydroxylated to 7-hydroxy-EFV by CYP2A6, a minor pathway of EFV 
metabolism accounting for approximately 20% of overall EFV metabolism in vitro.44  
 
Pharmacogenetics of EFV 
Genetic polymorphisms of enzymes involved in the EFV metabolism pathway have 
been extensively investigated for association with PK parameters, clinical outcomes 
and adverse events, such as its well established central nervous system (CNS) toxicity.45 
As CYP2B6 is responsible for most of EFV metabolism, the impact of its genetic  
polymorphisms on EFV toxicity, particularly neurological toxicity, is significant and 
has been extensively studied including in sub-Saharan African population groups.46 
The CYP2B6 516G→T single nucleotide polymorphism (SNP) has been shown to 
predict for increased plasma efavirenz exposure.47-52 This CYP2B6 516TT genotype is 
more common in Africans and African Americans than in Caucasians.52,53 Additional 
polymorphisms CYP2B6 983T→C and CYP2B6 15582C→T also predict increased 
plasma efavirenz exposure, however these are less common than the CYP2B6 516TT 
genotype in African population groups.47,54 The CYP2B6 983C allele is found almost 
exclusively with African ancestry.54 Polymorphisms in other genes of enzymes apart 
from CYP2B6, including CYP2A6 genes have also been infrequently reported to be 
associated with efavirenz concentrations.55  
Polymorphisms in CYP2B6 that predict higher efavirenz plasma concentrations 
predispose to efavirenz-mediated neurotoxicity and patients with CYP2B6 slow-
metabolizer genotypes also have higher CSF efavirenz exposure. In vitro studies have 
implicated efavirenz and especially its metabolite 8-hydroxy-efavirenz in neuronal 
toxicity.56  
Although a clear association with CYP2B6 genetic polymorphisms and EFV induced 
neurotoxicity exists, the same cannot be said of cases of EFV hepatotoxicity. Apart 
from an isolated case report of suspected EFV DILI (with corresponding 
histopathology) in a patient with CYP2B6 516G→T genotype,57 CYP2B6 
polymorphisms have not been shown to be a definitive risk factor for the development 




Side effect profile of EFV 
One of the most common side effects of EFV is neurotoxicity. These CNS side effects 
include insomnia, abnormal dreams, impaired concentration, amnesia, and 
hallucinations. These symptoms typically occur early in the course of therapy and can 
resolve spontaneously within a month despite continued use. However, some patients 
will have to discontinue the drug due to persistent symptoms.59,60 CNS toxicity has been 
reported more frequently in adult and paediatric patients with high EFV trough plasma 
concentrations >4 mcg/ml and as described relates to the “slow metabolizer” CYP2B6 
genotype common in sub-Saharan Africa.59. Other CNS neuropsychiatric effects 
include mood disorders, psychosis and suicidality. A late manifestation of EFV induced 
ataxia and encephalopathy has also been described.61 
Skin rashes, in the form of maculopapular eruptions, have also been described. This 
occurs more commonly in children and typically presents within the first two weeks 
after EFV initiation. Resolution is typical within one month of continued EFV use.62 
 
EFV use in the South African context  
Sub-Saharan Africa has the highest prevalence of HIV/AIDS in the world with an 
estimated overall HIV prevalence rate of approximately 12,6% among the South 
African population.63 In 2016, there were 7.1 million people living with HIV, among 
whom 56% were accessing antiretroviral therapy (ART).63 Among pregnant women 
living with HIV, more than 95% were accessing treatment to prevent mother-to-child 
transmission (MTCT).64 
 
EFV has formed part of the South African national first line ART since 2004. 
Subsequently with the introduction of FDC in 2015, EFV became the favored first line 
NNRTI when significant governmental policy and treatment regimen changes occurred 
to facilitate this change.64 Data from various case reports indicated an association of 
first trimester efavirenz exposure with central nervous system congenital 
anomalies.66,67 This resulted in a recommendation by the United States FDA in 2005 to 
avoid using efavirenz-based regimens in the first trimester of pregnancy due to concern 
for teratogenicity when EFV was changed from category C to category D.68 Birth 
defects included neural tube defects such as meningomyelocele and anophthalmia 66,67 
 
However, subsequent systematic reviews found no evidence of increased risk of 
congenital anomalies associated with first-trimester exposure to efavirenz. 69,70 As a 
result, in 2012, World Health Organisation (WHO)  recommended that efavirenz can 
be included as part of preferred first-line therapy in pregnant women and women of 
childbearing age.71 Importantly, all HIV positive pregnant women were prioritized for 
immediate ART initiation with EFV as first line therapy as the WHO had deemed it 
safe for use in pregnancy despite initial concerns.72 
 
 As a result, all HIV positive pregnant or breastfeeding women are currently 
commenced on lifelong ART with EFV as part of the first-line regimen regardless of 
CD4 count or gestation of the pregnancy.65 
 
In general, it is unclear if pregnancy independently increases the risk of developing 
ART hepatotoxicity.73 In particular, EFV pharmacokinetics does not appear to be 
altered in a clinically significant way.74 It is well known that the pharmacokinetics of 
many drugs are affected by physiological changes induced by pregnancy. For EFV, it 
has been shown that this is further affected by the pharmacogenetic profiles of the 
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population studied. In a Nigerian study, the combined effects of pregnancy and 
CYP2B6 polymorphisms showed significant differences in EFV pharmacokinetics 
based on CYP2B6 516G>T genotypes. The most significant differences were seen in 
patients with the CYP2B6 516GG genotype with the EFV Clearance (Cl/F) increasing 
by 100% (P = 0.0013) and the minimum concentration (Cmin) was reduced by 61.6% 
(P=0.0027) during pregnancy compared with postpartum.75 
  
Since 2014 the South African national ARV guidelines incrementally increased the 
initiating CD4 count first from 200 to 350, then 500, until the current “test and treat” 
strategy that recommends initiating ARV therapy irrespective of CD4 count.76 This was 
based on the findings of two pivotal randomized controlled trials (RCTs) published in 
2015: strategic timing of antiretroviral therapy (START) and TEMPRANO ANRS 
12136 (early antiretroviral treatment and early isoniazid prophylaxis against 
tuberculosis in HIV-infected adults) that showed significant individual clinical benefit 
from commencing ART immediately in patients with CD4 counts higher than 500 
cells/ul.77,78 
 
The WHO guidelines prior to the recent recommendation of Dolutegravir (DTG) in 
combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone as the 
preferred first-line ART regimen, 79 recommended efavirenz-based first-line ART, with 
dosing options of 600 mg or 400 mg available.80 EFV 600 mg has been the preferred 
dose in first-line ART as 400 mg was not available in FDCs. However, the ENCORE1 
study demonstrated that 400mg is non-inferior to 600mg dose of EFV at both 48 weeks 
and 96 weeks in terms of virological suppression and immune reconstitution. 
Importantly, the 400mg arm had 10% less adverse events, including hepatotoxicity, 
compared to the 600mg arm. However, this randomized controlled trial was designed 
mainly to address potential cost saving measures that a lower dose would achieve. 
Importantly, it excluded all pregnant women and patients who were taking TB 
treatment concurrently with EFV-containing ART.81 
 
These two exclusions have proven important in the South African context where TB 
prevalence is high. The HIV Clinicians Society of South Africa’s response to the 
ENCORE1 study has been to highlight the potential issues with drug-drug interactions 
between Rifampicin (RIF) and/or Isoniazid (INH) with EFV, as well as the concern 
regarding adequate dosing of EFV in pregnancy. Since no studies have been done using 
the reduced dose in pregnant women or patients on rifampicin-based TB treatment, 
guidelines had not recommended the routine use of the lower 400mg dose in first-line 
ART.82  
 
This recommendation was further supported by the outcome of a systematic review of 
the pharmacokinetics (PK) of efavirenz in patients on anti-TB therapy. When EFV was 
used at 600mg dosing, RIF and INH had a neglible effect on EFV plasma 
concentrations. However, recent studies using  EFV at 400 mg dosage have also shown 
similar provisional results. Although this may indicate that using a lower EFV dose is 
safe with the coadministration of anti-TB therapy, the full report is yet to be published 
and further studies particularly in high TB/HIV burden countries are warranted.83 
 
Conclusion 
Hepatotoxicity caused by EFV is well documented post initial drug marketing. The 
clinical features are quite varied, with some case reports of hypersensitivity responses 
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similar to NVP, and others a more delayed presentation of an idiosyncratic drug 
reaction.  
While molecular mechanisms have been postulated suggesting direct mitochondrial 
toxicity and autophagy as the predominant mechanism of injury, these in vitro studies 
are not in keeping with clinical or histopathological features described in cases of 
known EFV DILI. 
The safety of EFV for use in patients with chronic liver disease has not been established, 
but it is contraindicated in patients with severe hepatic impairment. Risk factors for 
developing the injury in the sub-Saharan African population  include female gender, 
high CD4 count nadir at drug initiation and younger age. While CYP2B6 
polymorphisms are well established as causative in the aetiology of the 
neuropsychiatric side effects of EFV, this is yet to be established as causal in EFV DILI. 
Apart from isolated case reports, there are no cohort studies or case series that detail 
the full natural history of the injury. Although steroid therapy is advised for the 
immunoallergic phenotype of injury, the exact duration of therapy is not well-
described. 
Thus, information regarding the natural history of EFV DILI in a prospective cohort 
study would provide new insight into this injury and provide important clinical 
information regarding time to clinical and biochemical injury, associated morbidity and 
mortality and could possibly identify further risk factors for this injury. This is 
important as EFV is likely to still be used particularly in women of reproductive age, 
despite the expected introduction of dolutegravir as first line therapy in the national 
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Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), has been a 
component of first line antiretroviral treatment in the South African HIV/AIDS 
programme since 2004.  Similarly, it is extensively used in ART programmes in other 
low and middle incomes countries.  The natural history of the previously reported EFV 
drug induced liver injury (DILI), is unknown.   
 
Objectives 
To establish causality assessment for the drug-induced liver injury and elucidate the 
natural history of EFV DILI by observing a cohort of patients through documenting all 
the factors influencing the patterns of clinical and histological injury, the time to clinical 
and biochemical recovery, the associated mortality rate and to establish if any 
demographic or clinical factors predict poor outcomes.  
 
Methods 
Patients were prospectively included after establishing causality criteria for EFV DILI. 
Clinical, demographic and histological features were carefully documented from the 
time of presentation and through follow up.  Prednisone at 0.25-0.5mg/kg was initiated 
at the discretion of the treating hepatologist. Risk factors for severe injury or death and 
time to event (full clinical recovery and full biochemical recovery) were analyzed. 
 
Results 
50 patients were included in the analysis, median age 34 (IQR 29-39) years, men 
significantly older than women, p=0.014.  Most (92%) were female gender, and of 
black African ethnicity (86%). The median duration on ART at time of presentation 
was 6.5 months with half of the women initiating ART during pregnancy at a median 
gestation of 24 weeks (IQR 11 – 36).  Median CD4 nadir at ART treatment initiation 
was 517 cells/mm3, with no significant difference (p=NS) in CD4 nadir in those 
pregnant or not.  Median RUCAM score was 7 and of the 66% of patients who had liver 
biopsies, 3 histological patterns were identified: submassive necrosis (57,5%), non-
specific hepatitis (36%) and mixed cholestatic hepatitis (6%).  Multivariate analysis 
suggested predictors for the development of submassive necrosis included age >30 
years [OR 0.86 (0.15-0.97), p=0.02], pregnancy [OR 6.9 (1.34 – 35.6), p=0.02];         
CD4 >350 [OR, 7.1 (1.5-31.9), p=0.02] but not alcohol [OR 1.17 (0.72-1.18); p=0.07]. 
For the non-specific hepatitis group, only pregnancy predicted [OR 8.7 (1.3-58.2), 
p=0.03].  The mortality rate was 14%, median time from admission to death was 15 
days with the median duration to initial hospital discharge 33 (IQR 24 -52) days. 
Biochemical recovery was prolonged necessitating a follow up period of more than a 
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Sub-Saharan Africa carries a considerable HIV/AIDS burden, the highest in the world.  
South Africa, an epicentre for HIV/AIDS, has an estimated adult HIV prevalence of 
approximately 12,6%.1  In 2016, an estimated 7.1 million South Africans were living 
with HIV, of whom 56% were accessing antiretroviral therapy (ART).2 More than 95% 
of HIV positive pregnant women were accessing treatment to prevent mother-to-child 
transmission (MTCT) of HIV.2  
 
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), has formed 
part of the South African national first line ART since 2004. Subsequently with the 
introduction of a fixed dose combination (FDC) formulation with tenofovir and 
emtricitabine, EFV became the favored first line NNRTI in 2015. A change in South 
African government policy necessitated the treatment program change.3 Importantly, 
HIV positive pregnant women were prioritized for immediate ART initiation with EFV 
based first line therapy when the World Health Organization (WHO) deemed it safe for 
use in pregnancy after initial concerns of EFV use in pregancy.4  As a result, all HIV 
positive pregnant or breastfeeding women are currently commenced on lifelong ART 
with EFV as part of the first-line regimen regardless of CD4 count or gestation of the 
pregnancy in many programmes, especially in low and middle income countries.3  
 
Since 2014, the South African national ARV guidelines incrementally raised the 
initiating CD4 count: first from 200 to 350, then to 500, eventually to the current “test 
and treat” strategy that recommends initiating ARV therapy irrespective of CD4 count.5 
This was based on the findings of two pivotal 2015 randomized controlled trials: the 
strategic timing of antiretroviral therapy (START) and TEMPRANO ANRS 12136 
(early antiretroviral treatment and early isoniazid prophylaxis against tuberculosis in 
HIV-infected adults) studies that demonstrated significant individual clinical benefit 
from commencing ART immediately in patients with CD4 counts higher than 500 
cells/mm3.6,7 
 
Several known side effects of EFV are well documented, most notably the 
neuropsychiatric adverse effects including insomnia, depression and the more recently 
recognized manifestation of EFV encephalopathy.8  These side effects are thought to 
be dose-related and can be attributed to the higher prevalence of the so-called “slow 
metabolizer” phenotypes where cytochrome P450 2B6 (CYP2B6) genotypic 
polymorphism combinations result in elevated plasma EFV concentrations in HIV-
infected African black adults and children consequent to slower EFV metabolism.9 
 
The WHO guidelines until recently have recommended efavirenz-based first-line ART, 
with dosing options of 600 mg or 400 mg available.10 EFV 600 mg has been the 
preferred dose in first-line ART as 400 mg is not currently available in FDCs. However, 
EFV 400 mg demonstrated non-inferior efficacy with improved tolerability in 
ENCORE 1.11  Given that no studies have been done using the reduced dose in pregnant 
women or patients on rifampicin-based Tuberculosis (TB) treatment, guidelines to date 
have not recommended the routine use of the lower 400mg dose in first-line ART.12  
 
Even though hepatotoxicity is well described within the non-nucleoside reverse 
transcriptase inhibitors class of antiretrovirals (ARVS), it is nevirapine (NVP) as 
opposed to EFV that has the higher reported incidence of drug induced liver injury 
(DILI). This well described hypersensitivity reaction is marked by rash, eosinophilia 
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and hepatitis (a DRESS phenomenon) and typically occurs early within the first three 
months of taking NVP.13  
 
Drug hepatotoxicity with EFV was well recognized but occurred at a frequency far less 
than NVP.  Furthermore, there were no particular characteristics ascribed to EFV 
hepatotoxicity. Although well recognised, the liver injury is not well described in 
particular with regards to natural history. In South Africa, however, 3 distinct 
clinicopathological patterns of Efavirenz-induced liver injury were described in 2016.  
One histological pattern in particular, submassive necrosis, was associated with 
significant morbidity and mortality.  The biochemical, clinical and histological features 
of this novel injury indicated that this was a severe injury requiring prolonged 
hospitalization and predictors of risk included female gender, higher CD4 nadir at drug 
initiation and younger age.14 
 
Very few data exists in the literature with respect to EFV DILI.  A few case reports 
describe strong causality with respect to suspected EFV DILI with little documented 
with respect to the natural history and clinical manifestations of the injury.15-18 
 
We elected to prospectively document the natural history of this novel injury noting all 
clinical and histological characteristics, management and clinical outcomes in terms of 
its morbidity and mortality. 
 
Methods 
We conducted an observational, prospective cohort study of patients presenting to the 
Division of Hepatology/Liver Clinic at Groote Schuur Hospital and identified as 
meeting causality criteria for EFV DILI from October 2014 until July 2016. Patients 
were included if they met strict causality assessment utilizing the RUCAM (Roussel 
Uclaf Causality Assessment Method) causality tool as the standard.19  The RUCAM 
scale involves a scoring system that categorizes the suspicion of a DILI into "definite 
or highly probable" (score >8), "probable" (score 6-8), "possible" (score 3-5), 
"unlikely" (score 1-2) and "excluded" (score ≤ 0). Ethics approval was obtained from 
the Faculty of Health Sciences Human Research Ethics Committee at the University 
of Cape Town (HREC REF 593/2018).  
 
The identified causality criteria for EFV DILI included: a temporal relationship to drug 
exposure and clinical disease, excluding acute viral hepatitis (hepatitis A, B, C and E); 
negative autoantibodies/elevated total immunoglobulin G and histology not 
compatible with autoimmune hepatitis (AIH); radiological exclusion of biliary and 
vascular obstruction; exclusion of alcohol/herbal toxins; observing the effects of drug 
de-challenge and a histological injury pattern compatible with a DILI. For viral 
hepatitis, hepatitis E was assessed by means of an in-house hepatitis E PCR test rather 
than serology, given the low sensitivity and specificity of many commercial kits.20 
Hepatitis A IgM, hepatitis B surface antigen and core IgM and hepatitis C antibody 
(Abbot ARCHITECT, Chicago, Illinois, USA), were screened to exclude acute 
hepatitis A, B and C.  
 
Patients were prospectively identified and once confirming causality for EFV DILI, 
relevant clinical and demographic data were collected on admission at the time of 
enrollment if informed consent was obtained.  At the discretion of the treating 
hepatologist, with sepsis excluded, patients were initiated on oral prednisone at 0.25 – 
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0.5 mg/kg dose - starting at a low dose and titrating according to response.  Once 
biochemical normality was achieved, progressive weaning of steroids occurred until 
complete discontinuation, at which time patients were discharged from the clinic.  
 
Patients’ clinical course and time to clinical and biochemical recovery was 
documented up to at least 12 months after initial presentation. Outpatient follow up 
occurred at the Liver Clinic, Groote Schuur Hospital.  All relevant biochemical data 
was documented. Clinical recovery was defined as clinically stable for discharge and 
follow-up as an outpatient. Biochemical recovery was defined as a return of liver 
profile to normal or to the patient’s baseline before or at start of Efavirenz-based ART. 
Cumulative dose of immunosuppressive therapy was extracted from the JAC 
Medicines Management System. The JAC system is utilized at over thirty hospital 
sites in the Western Cape and is South Africa’s first regional-scale deployment of an 
interconnected hospital pharmacy system that manages the hospital’s services 
electronically. 
 
As part of standard of care in assessing causality and requirement for corticosteroid 
therapy (presence of immune-allergic pattern of injury with inflammation), liver 
biopsies (including transjugular biopsies) were performed except where severe or 
uncorrectable coagulopathy precluded a safe procedure.  
Histological patterns of EFV DILI are immuno-allergic in nature and in standardizing 
EFV DILI histological patterns of injury reporting, the following 3 patterns were  
noted 14: 
Submassive necrosis (SMN): zonal/panzonal necrosis with inflammatory cell 
infiltrates composed of lymphocytes, plasma cells, and conspicuous eosinophils. 
Nonspecific hepatitis (NSH): portal and/or lobular inflammation particularly in zone 
3 with/without cholate stasis in zone 1, with inflammatory cells including lymphocytes 
and eosinophils. 
Mixed cholestatic hepatitis (MCH): combination of portal tract 
inflammation/interface hepatitis with inflammatory cells, including lymphocytes and 
eosinophils with marked zone 3 bilirubinostasis and a ductular reaction. 




Statistical analyses were performed using STATA statistical software, version 11.0. 
Demographic and clinical characteristics were summarized with descriptive statistics.   
Mean ± standard deviation was used for normally distributed data and median with 
interquartile ranges for non-parametric data. Continuous variables were compared 
using either student t-test (parametric) or Wilcoxon rank-sum test (non-parametric).  
Categorical variables were presented as frequencies and percentages and compared 
using Pearson’s X2 or Fisher’s exact test as appropriate. For laboratory data that 
included more than two groups, the Kruskal-Wallis was utilized for non-parametric 
data. Categorical variables were presented as frequencies and percentages and 
compared using Pearson’s X2 or Fisher’s exact test as appropriate.  
 
Multivariate analysis was performed on risk factors found significant on univariate 
analysis to identify factors predictive of various patterns of liver injury. Time to event 
(full clinical recovery and full biochemical recovery) were analyzed at 3, 6, 9 and 12 
months using the Kaplan-Meier method.  Factors associated with time to event were 
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analyzed using Cox Proportional Hazards regression.  All regression estimates were 
presented with 95% confidence intervals (CI). All P-values considered significant at 
p≤ 0.05.   
 
Results 
50 patients who met causality criteria for EFV DILI were prospectively included in the 
analysis and follow up. The baseline demographic characteristics of patients are listed 
in Table 1.  Notably, most patients (92%) were female gender, and of black African 
ethnicity (86%).  Median age was 34 (IQR 29-39) years, men significantly older than 
women, p=0.014, although notably the n-value for men was small. Median BMI was 
25.4 (IQR 22.7-30.5) kg/m2, ranging from normal to overweight BMI.  
 
The median duration on ART at time of presentation was 6.5 months, but the range was 
wide (IQR 5 -10 months), highlighting the long latency period to presentation with this 
drug injury. Half of the women initiated ART during pregnancy at a median gestation 
of 24 weeks (IQR 11 – 36).  Patients where ART was initiated in pregnancy presented 
a median 3 (IQR 2-6) months after delivery.  Notably, the median CD4 nadir at ART 
treatment initiation was 517 cells/mm3, with no significant difference (p=NS) in CD4 
nadir in those pregnant or not.   
 
With reported alcohol use, 28% drank alcohol although this typically did not exceed 
more than 4 units of alcohol per week. 
 
Of importance, autoimmune serology was positive in 9 patients, with one patient anti-
nuclear antibody and 8 anti-smooth muscle antibody positive.  The titers were all very 
low at ≤1:100.  Significantly, liver biopsies were not compatible with an autoimmune 
hepatitis pattern of injury.   
 
Two patients were coinfected with hepatitis B, both HBe-antigen negative and an 
undetectable hepatitis B DNA viral load at presentation.  Hepatitis C antibody was 
detected in no patients.  
 
For causality, the median RUCAM score was 7 – placing it in the probable category – 
with a RUCAM range of 6 – 9.  Of the 50 patients, 6 (12%) had received isoniazid 
preventive therapy, with 1 patient previously on cotrimoxazole prophylaxis.  The 
clinical course, histological findings and temporal relationship with drug use and 
clinical onset, were not compatible with isoniazid nor cotrimoxazole induced liver-
injuries. Given the severity of the injury, EFV was not rechallenged on any patients. 
Thus, the RUCAM score did not reflect the three potential additional points from a 
failed EFV rechallenge.  
 
Of the 66% (n=33) of patients who had liver biopsies, 3 histological patterns were 
identified: submassive necrosis [n=19 (57,5%)], non-specific hepatitis [n =12 (36%)] 
and mixed cholestatic hepatitis [n=2 (6%)].  All 3 of these patterns were associated with 
grade 4 ALT elevation (using the Modified AIDS Clinical Trial Group grading).21  
 
The most severe injury, clinically, biochemically, and histologically, was submassive 
necrosis.  At presentation (Table 3), jaundice was significantly greater with this pattern 
of injury compared to the non-specific hepatitis or mixed cholestatic hepatitis pattern 
respectively; total bilirubin 272; 93; 87 umol/l, respectively, p = 0.012.  This occurred 
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in the absence of a significant difference in ALT presentation in the 3 patterns, 713; 
927; 510 U/L, respectively, p=NS. Similarly, liver synthetic dysfunction at 
presentation, as measured by the international normalized ratio was significantly 
greater in the submassive necrosis group compared with the other 2 patterns of injury 
groups (1.72 vs. 1.19; p <0.0001) 
 
On multivariate analysis, predictors for the development of submassive necrosis 
included age >30 years [OR 0.86 (0.15-0.97), p=0.02], pregnancy [OR 6.9 (1.34 – 
35.6), p=0.02]; CD4 >350 [OR, 7.1  (1.5-31.9), p=0.02] but not alcohol use [OR 1.17 
(0.72-1.18); p=0.07]. For the non-specific hepatitis group, only pregnancy predicted 
[OR 8.7 (1.3-58.2), p=0.03].  
 
42 patients were treated with steroids.  The median duration of prednisone was 11 (IQR 
8-16) months with a cumulative prednisone dose of 3198 (IQR 1 898 – 4 670) 
milligrams. Ten patients had episodes of in-hospital sepsis, 3 were culture positive and 
7 were culture negative where a presumptive diagnosis based on clinical criteria was 
made. Steroid-induced diabetes occurred in 5 (10%) patients.  During follow up, 86% 
(37/43) were restarted successfully on protease inhibitor based ART and 70% (30/43) 
were virologically suppressed at last visit. 
 
No patients met clinical criteria for tuberculous immune reconstitution inflammatory 
syndrome (TB IRIS). Two patients were diagnosed with EFV encephalopathy 
concurrently with their presentation with drug-induced liver injury. Both had EFV 
levels >20mg/L (therapeutic range 1–4 mg/L).   Despite the immune-allergic nature of 
the liver histological pattern, no patients had any skin rash associated with EFV drug 
induced liver injury. 
 
The mortality rate was 14%, all deaths occurring in the first 15 days after presentation.   
The median duration of admission or time to initial discharge from hospital was 33 
(IQR 24 -52) days (Table 2). The median time to biochemical recovery (discharge from 
liver clinic) was 574 (IQR 239 – 728) days.  Graphs 1a, 1b and 1c denote the trend in 
recovery of parameters of the liver profile.  On univariate and multivariate analysis, 
there were no significant predictors for death. The Kaplan-Meier probability of death 
within 30 days was 10%. All deaths occurred in the patients who were not biopsied 
where coagulopathy precluded a safe procedure reflecting the severity of the liver 
injury. 
 
There were also no significant predictors for time to full biochemical recovery on both 
univariate and multivariate analysis.  
 
Discussion  
We report the first study documenting the natural history of EFV drug induced liver 
injury.  Several important features have emerged that allow for better insight into the 
clinical understanding and management of patients.  The consistently long latency 
period of 6 months from initiation of the efavirenz based ART to presentation, 
complicates clear guidance on surveillance of at risk patients. Furthermore, 
phenotypically, unlike nevirapine, there were no features of a hypersensitivity or 
DRESS type syndrome observed with the liver injury.  This compounds the difficulty 
in the detection of this drug injury.  Jaundice is a universal presenting feature and its 
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presence should prompt clinicians to immediately terminate therapy until confirmation 
of the DILI. 
 
Previous data suggested several predictors for the submassive necrosis pattern of 
injury, including female gender, CD4 count and younger age.14  Our study confirmed 
the finding of younger age and a higher baseline CD4 count. The predominance of 
female gender in this prospective cohort, is however intriguing.  Female gender has 
long been suggested as a risk factor for DILIs.22 However, this was questioned in a 
study from Iceland where female gender was not shown to be a risk factor for the 
development of DILI.23 This further emphasises the need for local studies addressing 
the risk factors for DILI. In our study, the association with initiating the drug in 
pregnancy, was another predictive factor, with almost half of the patients starting ART 
in pregnancy. These two parameters, gender and pregnancy are compelling, but we are 
unable to establish for bias given that HIV screening and treatment initiation is 
universal as part of antenatal care.  Hence, pregnant women are routinely screened and 
immediately linked to ART if HIV positive, irrespective of CD4 count.5 Further 
studies are required to understand the significance of the association of EFV DILI and 
pregnancy as it may have important programmatic implications for ARV programs 
using EFV as 1st line therapy in at risk populations. This may be a factor to be 
considered in recommending DILI surveillance in pregnant and postpartum women 
initiated on EFV in pregnancy, and whether EFV is even the best agent to be initiated 
in pregnancy.   
 
Although male patients were small in number, their CD4 count at ART initiation was 
significantly lower than females, in keeping with known HIV/AIDS epidemiology.24 
At lower CD4 counts, males developed the mixed cholestatic-hepatitic pattern of 
injury.  This is understandable given our finding that a high baseline CD4 count is a 
clear risk factor for the submassive necrosis pattern of injury.   
 
The morbidity and mortality with EFV DILI is substantial, characterized by the need 
for a prolonged hospital admission (median 38 days) and requiring a follow up period 
of more a year at an outpatient specialist clinic.   
 
The mortality rate of 14% is significant and is in keeping with “Hy’s Law”, stating 
that jaundice and a hepatocellular injury from a drug results in at least a 10% mortality 
rate.25 Death occurred within the first 2 weeks of admission in all patients with most 
of these deaths occurring early. These patients had an uncorrectable coagulopathy that 
precluded biopsy but very likely had submassive necrosis as their pattern of injury.  
  
The identification of this novel liver injury in 2016 did not lead to any significant 
programmatic changes in South Africa’s national ART guidelines. However, increased 
awareness of the injury was important in order to identify patients earlier and stop EFV 
appropriately. To this end, the Health Department acted to educate clinicians about the 
novel aspects of EFV DILI and the importance of improved pharmacovigilance.  
Likewise the regulator, the South African Health Products Regulatory Authority 
(SAHPRA), amended package inserts for efavirenz containing ART.  
 
As a consequence of the marked mixed inflammatory cell immune-allergic pattern of 
injury on liver biopsy, initiation of 0.25mg – 0.5mg/kg of prednisone was standard of 
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care, unless a contraindication precluded its immediate use. Weaning of 
corticosteroids with monitoring of liver enzymes commenced between 3- 6 months 
and in most patients was completed at 12 months, after initiation of new protease 
inhibitor based ART.  
 
Although positive autoimmune serology was present, albeit at low titres, in nine 
patients, the clinico-pathological correlation for autoimmune hepatitis was weak. 
Firstly, anti-smooth muscle antibodies can be non-specifically detectable in the setting 
of significant liver necrosis, as in submassive necrosis.26 Secondly, the histological 
findings were highly compatible with DILI and not autoimmune hepatitis including an 
inflammatory cell infiltrate composed of mostly lymphocytes and eosinophils and 
scanty plasma cells. Lastly, patients were all successfully weaned off steroid therapy 
in a relatively short space of time, an unlikely occurrence in autoimmune hepatitis. 
Biochemical stability was maintained off immunosuppression and the majority of 
patients were successfully rechallenged on a protease inhibitor (PI) based regimen. 
  
Further understanding of this liver injury, particularly the mechanisms at play in its 
aetiology, is crucial to identifying at-risk patients. These mechanisms are likely 
multifactorial including genetic, possibly related to CYP2B6 polymorphisms, as well 
as immunological, given the higher CD4 counts in patients with the most aggressive 
histological and clinical patterns of injury.27  Exactly what these factors are, almost 
certainly related to both HLA and non-HLA haplotype polymorphisms or variants,  
warrant further study. Also, with the number of patients accessing ART in a population 
with an identifiable genetic predisposition to the “slow metaboliser” phenotype of 
CYP2B6 polymorphisms 9, genetic studies are necessary to potentially identify tests 
that could easily identify at risk patients for EFV DILI in sub-Saharan Africa.   
 
In 2017, the Health Department reported that the integrase inhibitor, dolutegravir, was 
to replace efavirenz as part of first-line ART.  The newly formulated fixed dose 
combination with an integrase inhibitor promised not only a better tolerated first line 
regimen but also significant cost savings for the national ART program.28 The benefits  
of dolutegravir include not only significant cost-savings,29 but also proven efficacy in 
the treatment of HIV,30 fewer treatment discontinuations due to adverse events31  and a 
high barrier to the development of resistance.32 However, subsequent concerns 
regarding reported teratogenicity of dolutegravir, specifically neural tube defects,33,34 
has delayed this important programmatic change which is now planned for 2020.  The 
WHO’s response to date has been to revert to their 2016 guidelines which recommend 
an efavirenz-based regimen for women who intend becoming pregnant or are not using 
effective contraception, to avert the potential period of risk for the development of 
neural tube defects.35  SAHPRA have also issued recommendations on the use of 
dolutegravir among women of reproductive age.36,37 It is thus likely that future national 
guidelines may advise against the use of dolutegravir in pregnancy, meaning EFV will 
remain the ARV of choice in pregnancy.38 
 
Considering this, it remains important to further establish and define risk factors for 
this injury  and  continue to advocate for improved pharmacovigilance particularly for 
high risk groups especially pregnant women. It is important to note that the hepatoxicity 
of EFV was not initially appreciated at the time of initial registration of the drug in the 
late 1990’s. This emphasises the need for continued drug surveillance post drug 
marketing, especially in population groups not included in the initial drug trials.  This 
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phenomenon is not unique to efavirenz, but holds true for many newer therapies, 
seldom trialed in low and middle income countries in the initial registration studies.         
 
The cohort size is relatively small and can be considered a study limitation, however 
for a DILI, the numbers are significant.  The cohort also represents a single centre study, 
although it is a regional and supraregional referral centre. The study was not 
significantly powered to be able to identify any significant predictors for death or 
prolonged time to recovery. However, given the fact that the natural history of EFV 
DILI has never been described, it provides important insight into the severity of the 





EFV DILI is a novel and severe injury associated with both significant morbidity and 
mortality.  Hospital admission and outpatient follow up is prolonged with need for 
adjunctive steroid therapy. CD4 counts >350 cells/mm3, younger age and ART initiated 
in pregnancy were predictive for development of the severe submassive necrosis 
histological pattern of injury. EFV is likely to still be used particularly in women of 
reproductive age, despite the expected introduction of dolutegravir as first line therapy 
in the national ART program. Furthermore, the drug will likely remain in use in other 
low and middle income countries for the forseeable future. It is therefore vitally 
important to further elucidate the mechanisms underlying the injury as well as improve 
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Table 1: Baseline Demographic Data 
                Parameters   
 
          n = 50* 




  Female 






  34 [29- 39] 
  34 [29-38] 
  43 [39-49] 
 
 
  46 (92%) 






              Black African 
              Mixed Ancestry 
 
  43 (86%) 
    7 (14%) 
 
Body Mass Index (kg/m2)    25 [22-33]  
ARVS initiated in pregnancy  
Months Post-Partum at Presentation  
  23 (46%) 
    3 [2-6] 
 
 
CD4 (cells/mm3) ^ 
              Pregnant (n = 23) 
              Non pregnant (n = 27)$ 
 
                     Female 

















Duration on ART (months):   
 
Alcohol consumption# n (%) 
 
HBsAg Positive n (%) 
       HBV core IgM Positive        
       HBV Surface Antigen Positive 
       HBV Viral Load <20 IU/ml 
 
HCV Antibody Positive n (%) 
 
HEV IgM Antibody Positive n (%) 
        HEV PCR Positive  
 
Autoimmune serology 
       Antinuclear antibody positive n (%) 
       Anti-smooth muscle antibody positive n (%) 
                         Titre 1:100 
Anti-liver kidney microsomal type 1 antibody 
positive  n (%) 
        
 









  0 (0%) 
 













Medication use n (%) 
          Cotrimoxazole (Bactrim) 
          Isoniazid (INH) prophylaxis 
          Anti-TB drugs (Rifafour) 
          Fluconazole 
          Herbal/Traditional 










  *Data expressed as median and interquartile range [IQR] 
  # Defined as consuming any alcohol >1 unit per week 
  $ Included 4 males 
  ^ CD4 nadir 
 
Abbreviations: ARVS, antiretrovirals; ART, antiretroviral therapy;                        
HBsAg, Hepatitis B surface antigen; HBV, Hepatitis B; HCV, Hepatitis C; 




































Table 2: Clinical features & Outcome 
 n = 50 
Clinical features: 
   Jaundice 
   Skin Rash 
   EFV Encephalopathy  
Clinical criteria for TB immune    
reconstitution inflammatory syndrome (IRIS) 
   Median RUCAM score (range) 
 
47 (94%) 
                       0 
2 (4%) 




Recovery n (%) 
 
Median duration of admission days 
(time to clinical recovery) 
Median duration of outpatient follow up (time 
to biochemical recovery) 
Death n (%) 
Time to death (days) 
 
 
Lost to follow up n (%) 
 




Duration on steroids (prednisone) (months) 
 
Complications 
Sepsis (culture positive) n (%) 
Sepsis (culture negative) n (%) 
Steroid induced Diabetes Mellitus n (%) 
 








    33 (24 – 52) 
 












11 (8 – 16) 
 
 





                    16 
                    20 
                      1 
                      6 
                                      
                             
Abbreviations:  EFV, Efavirenz; IRIS, Immune Reconstitution Inflammatory 








Table 3: Laboratory parameters of the three histological patterns of efavirenz-

































































Laboratory parameter (laboratory reference range). Data are expressed as 
median and interquartile ranges.  
Total and Conjugated Bilirubin, (umol/L); ALT, alanine aminotransferase (U/L); 
AST, aspartate aminotransferase (U/L); ALP, alkaline phosphatase (U/L); GGT, g-
glutamyl transferase (U/L); INR, international normalized ratio.                                       






















OR (95%CI)        P-value 
Age >30 years  0.5 (0.1-3.1)         0.4 0.86 (0.15-0.97)     0.02 




5.6 (0.9-32.6)        0.06 
 
7.1 (1.5-31.9)         0.02 
 
Alcohol use  
 
0.17 (0.03-1.6)       0.1 
 




























Graph 1a: Trends in Recovery of Liver Profile: Median liver profile parameters  
 
 
Total and Conjugated Bilirubin, (umol/L); ALT, alanine aminotransferase (U/L); 
AST, aspartate aminotransferase (U/L); ALP, alkaline phosphatase (U/L); GGT, g-































          
 








ALT, alanine aminotransferase (U/L); AST, aspartate aminotransferase (U/L);        




AST ALP   
 
 GGT  
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Graph 1c: Median Total and Conjugated bilirubin over 1 year of follow up 
 
 







































Appendix 1: Instructions to authors (South African Medical Journal) 
Research  
Guideline word limit: 4 000 words 
 Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: 
introduction, methods, results, discussion and conclusion, and should include a 
structured abstract (see below). The introduction should be concise – no more than 
three paragraphs – on the background to the research question, and must include 
references to other relevant published studies that clearly lay out the rationale for 
conducting the study. Some common reasons for conducting a study are: to fill a gap 
in the literature, a logical extension of previous work, or to answer an important 
clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods 
in as much detail as possible so that others would be able to replicate the study should 
they need to. Results should describe the study sample as well as the findings from 
the study itself, but all interpretation of findings must be kept in the discussion 
section, which should consider primary outcomes first before any secondary or 
tertiary findings or post-hoc analyses. The conclusion should briefly summarise the 
main message of the paper and provide recommendations for further study. 
 Select figures and tables for your paper carefully and sparingly. Use only those 
figures that provided added value to the paper, over and above what is written in the 
text. 
Do not replicate data in tables and in text . 
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other 
published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, 
description of the intervention, primary and secondary outcomes, any 
specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample 
description; outline the results according to the methods described. 
Primary outcomes must be described first, even if they are not the most 
significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations 
for further study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and 
has been approved by all authors. 
• Do not include any references in the abstracts. 




All articles are to include the following main sections: Introduction/Background, 
Methods, Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main 
aim of the study and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, 
randomisation, blinding, placebo control, case control, crossover, criterion 
standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of 
participating centres. 
• Participants (instead of patients or subjects; within Methods): numbers 
entering and completing the study, sex, age and any other biological, 
behavioural, social or cultural factors (e.g. smoking status, socioeconomic 
group, educational attainment, co-existing disease indicators, etc)that may 
have an impact on the study results. Clearly define how participants were 
enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically 
for randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, 
and those ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key 
characteristics of comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, 
where appropriate, the exact level of statistical significance and the number 
need to treat/harm. Whenever possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house 
style is to present this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± 
symbol for mean (SD). 
• Leave interpretation to the Discussion section. The Results section should just 
report the findings as per the Methods section.  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-
headings are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
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• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and 
policymakers 
• Unanswered questions and recommendations for future research  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include 
primary conclusions and their implications, suggesting areas for further research if 
appropriate. Do not go beyond the data in the article. 
Tables 
• Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. 
• Large tables will generally not be accepted for publication in their entirety. 
Please consider shortening and using the text to highlight specific important 
sections, or offer a large table as an addendum to the publication, but available 
in full on request from the author 
• Embed/include each table in the manuscript Word file - do not provide 
separately as supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to 
consecutively in the text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and 
editable. 
• Ensure each table has a concise title and column headings, and include units 
where necessary. 
• Footnotes must be indicated with consecutive use of the following symbols: * 
† ‡ § ¶ || then ** †† ‡‡ etc.  
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of 
reference manager software. Endnotes must not be used. 
• Authors must verify references from original sources. 
• Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of 
appearance in the Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals 
in Index Medicus. 
• Names and initials of all authors should be given; if there are more than six 
authors, the first three names should be given followed by et al. 
• Volume and issue numbers should be given. 
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
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• Wherever possible, references must be accompanied by a digital object 
identifier (DOI) link). Authors are encouraged to use the DOI lookup service 
offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata 
search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
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